Research programme: autoimmune disease therapeutics - Kanyos Bio
Latest Information Update: 07 Jul 2015
At a glance
- Originator Kanyos Bio
- Mechanism of Action Immunosuppressants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Coeliac disease; Type 1 diabetes mellitus
Most Recent Events
- 07 Jul 2015 Preclinical trials in Type-1 diabetes mellitus in USA (unspecified route)
- 07 Jul 2015 Preclinical trials in Coeliac disease in USA (unspecified route)